<scp>d</scp>-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy
Clive Kearon(McMaster University), Sameer Parpia(University of North Carolina at Chapel Hill), Luciana Spadafora(University of North Carolina at Chapel Hill), Trevor Baglin(Cambridge University Hospitals NHS Foundation Trust), Stephan Moll(University of North Carolina at Chapel Hill), Craig M. Kessler(Georgetown University), Scott M. Stevens(Intermountain Medical Center), Scott Kaatz(Hurley Medical Center), Jean M. Connors(Harvard University), Steven R. Lentz(University of Iowa), Jim A. Julian(McMaster University), Frederick A. Spencer(McMaster University), Sam Schulman(Thrombosis and Atherosclerosis Research Institute), Denis O’Keeffe(University Hospital Limerick), James D. Douketis(Thrombosis and Atherosclerosis Research Institute), Jeffrey S. Ginsberg(Thrombosis and Atherosclerosis Research Institute), Kenneth A. Bauer(VA Boston Healthcare System)
Cited by 146
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k